Summary:
- The U.S. Food and Drug Administration (FDA) has approved the expanded use of the medication Vonvendi to treat von Willebrand disease, a rare genetic disorder that affects blood clotting.
- Vonvendi can now be used to treat bleeding episodes and for the prevention of excessive bleeding during and after surgery in both adults and children with von Willebrand disease.
- This approval is significant as it provides a new treatment option for children with this condition, helping to manage their symptoms and improve their quality of life.